Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Genomic subtypes of non-muscle-invasive bladder cancer: guiding immunotherapy decision-making for patients exposed to aristolochic acid.

Molecular medicine (Cambridge, Mass.) - 17 Apr 2025

Peng Yun, Song Yuxuan, Qin Caipeng, Ding Mengting, Huang Zixiong, Wang Fei, HuangFu Yuchao, Yu Luping, Du Yiqing, Xu Tao

Abstract excerpt

BACKGROUND: The limited genomic data on non-muscle-invasive bladder cancer (NMIBC) hampers our understanding of its carcinogenesis and development. Specifically, Aristolochic acid (AA), a potent human carcinogenic compound from aristolochia plants and commonly found in Chinese herbal medicine, has been extensively documented as being closely associated with the onset and progression of bladder cancer. However,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Infectious Disease Case Reports and Treatments
Share to Multiple and Secondary Primary Cancers

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Nephrotoxicity and Medicinal Plants

Source

Open in PubMed Open full text

Identifiers

PMID: 40247187
DOI: 10.1186/s10020-025-01199-1
PMCID: PMC12004710

Genes

FGFR3
HRAS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 23 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Genomic subtypes of non-muscle-invasive bladder cancer: guiding immunotherapy decision-making for patients exposed to aristolochic acid.PMID 40247187Read ↗

Mutation signatures implicate aristolochic acid in bladder cancer developmentSemantic proximity Read ↗

Aristolochic acid mutational signature defines the low-risk subtype in upper tract urothelial carcinoma.Semantic proximity Read ↗

Molecular profiles and urinary biomarkers of upper tract urothelial carcinomas associated with aristolochic acid exposure.Semantic proximity Read ↗

Mutational signature and prognosis in adenocarcinoma of the bladder.Semantic proximity Read ↗

Aristolochic acids and their derivatives are widely implicated in liver cancers in Taiwan and throughout Asia.Semantic proximity Read ↗

Aristolochic acid-related renal cell carcinoma exhibits a distinct tumor-immune microenvironment favoring response to immune checkpoint blockade.Semantic proximity Read ↗

Genome-wide mutational signatures of aristolochic acid and its application as a screening tool.Semantic proximity Read ↗

Mutational signatures in upper tract urothelial carcinoma define etiologically distinct subtypes with prognostic relevanceSemantic proximity Read ↗

Comprehensive genomic profiling of neuroendocrine bladder cancer pinpoints molecular origin and potential therapeutics.Semantic proximity Read ↗

Beyond driver mutations: exploring the landscape of mutational signatures in adenocarcinomas of the bladder†.Semantic proximity Read ↗

EGFR as a potential therapeutic target for a subset of muscle-invasive bladder cancers presenting a basal-like phenotype.Semantic proximity Read ↗

Racial differences in genomic features and new trans-ancestry prognosis subtypes in bladder cancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.